Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes

Diabetes Care

Volumn 28, Issue 2, 2005, Pages 254-259

  Janka, Hans U ^a,e   Plewe, Gerd ^a   Riddle, Matthew C ^b   Kliebe Frisch, Christine ^c   Schweitzer, Matthias A ^c   Yki Järvinen, Hannele ^d  

^a Zentralkrankenhaus   (Germany)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

^d UNIVERSITY OF HELSINKI   (Finland)

^e II Medizinische Abteilung   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLIMEPIRIDE; HEMOGLOBIN A1C; INSULIN GLARGINE; METFORMIN; SULFONYLUREA;

ADULT; AGED; ALGORITHM; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL DISEASE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUROLOGIC DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SCREENING TEST;

ADULT; AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MALE; METFORMIN; MIDDLE AGED; SULFONYLUREA COMPOUNDS; WEIGHT GAIN;

EID: 12844276465     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.28.2.254     Document Type: Article

References (17)

1. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853, 1998
2. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M: Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 28:103-117, 1995
3. The Diabetes Control and Complications Trial Research Group: The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. Diabetes 45:1289-1298, 1996
4. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Madden D, Turner RC, Holman RR: Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321:405-411, 2000
5. European Diabetes Policy Group 1999: A desktop guide to type 2 diabetes mellitus. Diabet Med 16:716-730, 1999
6. American Diabetes Association: Standards of medical care for patients with diabetes mellitus (Position Statement). Diabetes Care 25:S33-S49, 2002
7. Koivisto V, Tuominen J, Ebeling P: Lispro Mix25 insulin as premeal therapy in type 2 diabetic patients. Diabetes Care 22:459-462, 1999
8. Hauner H, Koster L, von Ferber L: Prevalence of diabetes mellitus in Germany 1998-2001. Dtsch Med Wochenschr 128: 2632-2637, 2003
9. Lepore M, Pampanelli S, Fanelli C, Porcellati F, Bartocci L, Di Vincenzo A, Cordoni C, Costa E, Brunetti P, Bolli GB: Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 49:2142-2148, 2000
10. Heinemann L, Linkeschova R, Rave K, Hompesch B, Sedlak M Heise T: Time-action profile of the long-acting insulin analog glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 23:644-649, 2000
11. Korythowski M: When oral agents fail: practical barriers to starting insulin. Int J Obes Relat Metab Disord 26:S18-S24, 2002
12. Johnson R, Hauber B, Bolinder B: Trade-offs between glucose control and hypoglycemia in different patient types: results of a 5-country physician survey (Abstract). Diabetes 52 (Suppl. 1):A264, 2003
13. Fritsche A, Haring H-U, Tögl E, Schweitzer M-A, the HOE901/4001 Study Group: Treat-to-target with add-on basal insulin: can glargine reduce barrier to target attainment? (Abstract). Diabetes 52(Suppl. 1):A119, 2003
14. Cefalu WT: Evaluation of alternative strategies for optimizing glycemia: progress to date. Am J Med 113 (Suppl. 6A):23S-35S, 2002
15. Yki-Järvinen H, Kauppila M, Kujansuu E, Lahti J, Marjanen T, Niskanen L, Rajala S, Ryysy L, Salo S, Seppälä P, Tulokas T, Viikari J, Karjalainen J, Taskinen M-R: Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 327:1426-1433, 1992
16. Wolffenbuttel BH, Sels JP, Rondas-Colbers GJ, Menheere PP, Nieuwenhuijzen Kruseman AC: Comparison of different insulin regimens in elderly patients with NIDDM. Diabetes. Care 19:1326-1332, 1996
17. Olsson PO, Lindstrom T: Combination-therapy with bedtime NPH insulin and sulphonylureas gives similar glycemic control but lower weight gain than insulin twice daily in patients with type 2 diabetes. Diabetes Metab 28:272-277, 2002